Home

Bristol-Myers Squibb (BMY)

46.86
-1.66 (-3.42%)
NYSE · Last Trade: Jul 12th, 4:55 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close48.52
Open47.75
Bid46.84
Ask46.90
Day's Range46.72 - 47.80
52 Week Range39.92 - 63.33
Volume13,716,475
Market Cap104.13B
PE Ratio (TTM)17.55
EPS (TTM)2.7
Dividend & Yield2.480 (5.29%)
1 Month Average Volume14,375,097

Chart

About Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a strong focus on oncology, immunology, cardiology, and fibrotic diseases, the company utilizes advanced science and research to create life-changing therapies. Bristol-Myers Squibb emphasizes collaboration and partnerships with healthcare professionals, researchers, and patients to enhance treatment outcomes and improve quality of life. The company is committed to addressing unmet medical needs through its comprehensive portfolio of prescription medications and is actively engaged in ongoing research to advance healthcare solutions. Read More

News & Press Releases

Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other headwinds. Ahead of its second-quarter earnings report, UBS reiterated its "Neutral" rating on the stock. The firm's note pointed to several challenges, including an expected $1.5 billion expense for in-process research and development (IPR&D) related to a collaboration with BioNTech. This charge is anticipated to reduce the company's earnings per share (EPS) by approximately $0.60. The report also touched on broader investor concerns, such as the impact of Medicare's Part D redesign on several of the company's high-priced drugs and the looming patent expirations for key products. These factors contribute to a more cautious outlook on the pharmaceutical giant's near-term profitability and growth prospects. 
Via StockStory · July 11, 2025
Top S&P500 movers in Friday's sessionchartmill.com
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · July 11, 2025
What's going on in today's session: S&P500 moverschartmill.com
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via Chartmill · July 11, 2025
Price Over Earnings Overview: Bristol-Myers Squibbbenzinga.com
Via Benzinga · July 4, 2025
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?benzinga.com
MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with Opdivo.
Via Benzinga · July 11, 2025
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · July 11, 2025
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Leviesbenzinga.com
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via Benzinga · July 11, 2025
2 Top Stocks Down 16% and 17% This Year to Buy and Holdfool.com
Via The Motley Fool · July 11, 2025
Why Is AbbVie Stock Trading Higher On Thursday?benzinga.com
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.
Via Benzinga · July 10, 2025
What Analysts Are Saying About Bristol-Myers Squibb Stockbenzinga.com
Via Benzinga · July 10, 2025
Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiarybenzinga.com
Warren Buffett is indirectly invested in high-dividend yield stocks via Berkshire Hathaway Inc.'s subsidiary New England Asset Management.
Via Benzinga · July 9, 2025
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers.
Via StockStory · July 8, 2025
Warren Buffett Owns 9 Ultra-High-Yield Dividend Stocks. Here's the Best of the Bunch.fool.com
Via The Motley Fool · July 7, 2025
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatmentbenzinga.com
Via Benzinga · July 3, 2025
Is Pfizer Stock a Yield Trap?fool.com
Via The Motley Fool · July 3, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · July 2, 2025
3 Large-Cap Stocks Skating on Thin Ice
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Via StockStory · July 2, 2025
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancersbenzinga.com
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
Via Benzinga · June 30, 2025
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Consideringchartmill.com
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.29% dividend yield, strong profitability, and a reasonable valuation, making it a compelling choice for dividend investors.
Via Chartmill · June 28, 2025
FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancersbenzinga.com
FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety program requirements.
Via Benzinga · June 27, 2025
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of large B cell lymphoma (LBCL) and other lymphomas and Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of multiple myeloma. These label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) programs that had been in place since each product was initially approved.
By Bristol Myers Squibb · Via Business Wire · June 26, 2025
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopesinvestors.com
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.
Via Investor's Business Daily · June 26, 2025
Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2B Cancer Drugbenzinga.com
Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.
Via Benzinga · June 25, 2025
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Stock Worth Consideringchartmill.com
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers strong profitability, a high dividend yield, and an attractive valuation, making it a potential pick for value investors.
Via Chartmill · June 23, 2025
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best and worst performers in the branded pharmaceuticals industry.
Via StockStory · June 18, 2025